We prospectively investigated the safety and efficacy of sunitinib using a modified regimen (2 weeks on/1 week off) in 24 patients (22 males, 2 females; age range 39-86 years, median 64 years) with metastatic renal cell carcinoma (RCC).
During the observation period (3-62 weeks, median 21 weeks), thrombocytopenia was seen in 13 (54.2%), leukopenia in 11 (45.8%), hand-foot syndrome in 5 (20.8%), hypertension in 4 (16.7%), and hypothyroidism in 3 (12.5%) patients, while grade 3 or higher adverse events were found in 4 (16.7%), 1 (4.2%), 1 (4.2%), 2 (8.3%), and 0 patients, respectively. Of the 21 patients evaluable for response, 5 (23. 8%) showed partial response, 8 (38.1%) stable disease, and 8 (38.1%) progressive disease. This new modified regimen may lead to a reduction in adverse events for treatment of patients with metastatic RCC as a substitute for the standard dosing regimen of sunitinib.
Written by:
Togo Y, Shimatani K, Hanasaki T, Yo T, Nakanishi Y, Nagasawa S, Hashimoto T, Shiraishi Y, Taoka R, Suzuki T, Go S, Higuchi Y, Kanematsu A, Nojima M, Tsuchihashi K, Makino Y, Shimizu Y, Kanamaru S, Kono Y, Matsumoto K, Utsunomiya N, Ito N, Kawakita M, Yamamoto S. Are you the author?
The Department of Urology, Hyogo College of Medicine; The Department of Urology, Nishi Kobe Medical Center; The Department of Urology, Kobe City Medical Center General Hospital.
Reference: Hinyokika Kiyo. 2014 May;60(5):209-14.
PubMed Abstract
PMID: 24894855
Article in Japanese.
UroToday.com Renal Cancer Section
